Trial Profile
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double Blind Study to Assess the Safety and Efficacy of CC-486 (Oral Azacitidine) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo in Subjects With Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Feb 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Pembrolizumab
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 12 Jan 2023 Planned End Date changed from 2 Apr 2023 to 3 Apr 2024.
- 21 Jan 2022 Planned End Date changed from 30 Apr 2022 to 2 Apr 2023.
- 09 Jun 2021 Planned End Date changed from 31 Mar 2022 to 30 Apr 2022.